Home
Productsindex
Gene
mRNA Productsindex
mRNAs for Replacement Therapy Developmentlists
Factor VIII In Vitro Transcribed mRNA-LNP
SG-MRNA-LNP-1870
Factor VIII In Vitro Transcribed mRNA-LNP
Source:The ORF of Factor VIIIwas cloned in our IVT vector and mRNA was prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).
Alternative Names:Factor VIII
SKU:SG-MRNA-LNP-1870-DCPS
Product Name:Factor VIII In Vitro Transcribed mRNA-LNP(DSPC:Cholesterol:DMG-PEG:SM102)
Product Description:Factor VIII In Vitro Transcribed mRNA encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102)
SKU:SG-MRNA-LNP-1870-DCPS
Product Name:Factor VIII In Vitro Transcribed mRNA-LNP(DSPC:Cholesterol:DMG-PEG:SM102)
Product Description:Factor VIII In Vitro Transcribed mRNA encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102)
PROPERTIES
Cap:
m7GpppN
5'-UTR:
5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF:
Factor VIII
3'-UTR:
3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail:
A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.
Modifications:
N1-methyl-pseudouridine
Neutral Lipid:
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol:
Cholesterol
Lonizable Lipid:
1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid:
Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)− 8-oxooctyl)amino)octanoate)(SM-102)
Storage:
-20 °C
Buffer:
PBS, pH7.4
Cryoprotectant:
Trehalose
Background

Gene Alias

Factor VIII

Background

Factor VIII is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated.1 It is not indicated for patients with severe (i.e. type 3) von Willebrand Disease whom are undergoing major surgery.

RECOMMENDED PRODUCTS
BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
ABL1

SGRP00624

BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
ABL1

SGRP00628

BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
AKT1

SGRP00630

BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
AKT1

SGRP00631

BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
ALK

SGRP00637

BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
View Price and Availability
0.125338s